Key Insights

Highlights

Treatment Research

2 treatments under study, led by Dinutuximab Beta

Research Leaders

5 sponsors active, led by National Cancer Institute, France

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07853105Phase 1/2Not Yet Recruiting

Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.

Showing all 1 trials

Research Network

Common Treatments

  • Dinutuximab Beta1
  • Dinutuximab Beta Sirolimus And Irinotecan1

Active Sponsors

  • National Cancer Institute, France1
  • Les Hopitaux Universitaires De Strasbourg1
  • Ministry of Health, France1
  • Recordati Rare Diseases Inc1
  • University Hospital, Strasbourg, France1

Top Investigators

Related Conditions

  • Bone Cancer1
  • Ewing Sarcomas1
  • Osteosarcomas1
  • Ewinglike Tumors With Rare Fusions1
  • Chondrosarcomas1

Activity Timeline